Literature DB >> 21628462

Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors.

Audrey Guillon-Munos1, Katerina Oikonomopoulou, Noémie Michel, Chistopher R Smith, Agnès Petit-Courty, Sylvie Canepa, Pascale Reverdiau, Nathalie Heuzé-Vourc'h, Eleftherios P Diamandis, Yves Courty.   

Abstract

Kallikrein-related peptidases (KLKs) are an emerging group of secreted serine proteases involved in several physiological and pathological processes. We used a degradomic approach to identify potential substrates of KLK12. MDA-MB-231 cells were treated either with KLK12 or vehicle control, and the proteome of the overlying medium was analyzed by mass spectrometry. CCN1 (cyr61, ctgf, nov) was among the proteins released by the KLK12-treated cells, suggesting that KLK12 might be responsible for the shedding of this protein from the cell surface. Fragmentation of CCN1 by KLK12 was further confirmed in vitro, and the main cleavage site was localized in the hinge region between the first and second half of the recombinant protein. KLK12 can target all six members of the CCN family at different proteolytic sites. Limited proteolysis of CCNs (cyr61, ctgf, nov) was also observed in the presence of other members of the KLK family, such as KLK1, KLK5, and KLK14, whereas KLK6, KLK11, and KLK13 were unable to fragment CCNs. Because KLK12 seems to have a role in angiogenesis, we investigated the relations between KLK12, CCNs, and several factors known to be involved in angiogenesis. Solid phase binding assays showed that fragmentation of CCN1 or CCN5 by KLK12 prevents VEGF(165) binding, whereas it also triggers the release of intact VEGF and BMP2 from the CCN complexes. The KLK12-mediated release of TGF-β1 and FGF-2, either as intact or truncated forms, was found to be concentration-dependent. These findings suggest that KLK12 may indirectly regulate the bioavailability and activity of several growth factors through processing of their CCN binding partners.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21628462      PMCID: PMC3138267          DOI: 10.1074/jbc.M110.213231

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  65 in total

1.  Antiproliferative activity of CCN3: involvement of the C-terminal module and post-translational regulation.

Authors:  A M Bleau; N Planque; N Lazar; D Zambelli; A Ori; T Quan; G Fisher; K Scotlandi; B Perbal
Journal:  J Cell Biochem       Date:  2007-08-15       Impact factor: 4.429

2.  Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs).

Authors:  Katerina Oikonomopoulou; Kristina K Hansen; Mahmoud Saifeddine; Nathalie Vergnolle; Illa Tea; Michael Blaber; Sachiko I Blaber; Isobel Scarisbrick; Eleftherios P Diamandis; Morley D Hollenberg
Journal:  Biol Chem       Date:  2006-06       Impact factor: 3.915

3.  Proteolytic processing of human growth hormone by multiple tissue kallikreins and regulation by the serine protease inhibitor Kazal-Type5 (SPINK5) protein.

Authors:  Nahoko Komatsu; Kiyofumi Saijoh; Norio Otsuki; Tadaaki Kishi; Iacovos P Micheal; Christina V Obiezu; Carla A Borgono; Kazuhiko Takehara; Arumugam Jayakumar; Hua Kang Wu; Gary L Clayman; Eleftherios P Diamandis
Journal:  Clin Chim Acta       Date:  2006-10-19       Impact factor: 3.786

Review 4.  Role of Annexin-II in GI cancers: interaction with gastrins/progastrins.

Authors:  Pomila Singh
Journal:  Cancer Lett       Date:  2006-12-22       Impact factor: 8.679

Review 5.  A potential role for tissue kallikrein-related peptidases in human cervico-vaginal physiology.

Authors:  Julie L V Shaw; Eleftherios P Diamandis
Journal:  Biol Chem       Date:  2008-06       Impact factor: 3.915

Review 6.  Human tissue kallikreins as promiscuous modulators of homeostatic skin barrier functions.

Authors:  Azza Eissa; Eleftherios P Diamandis
Journal:  Biol Chem       Date:  2008-06       Impact factor: 3.915

7.  Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain.

Authors:  S Soker; H Fidder; G Neufeld; M Klagsbrun
Journal:  J Biol Chem       Date:  1996-03-08       Impact factor: 5.157

Review 8.  Functions and mechanisms of action of CCN matricellular proteins.

Authors:  Chih-Chiun Chen; Lester F Lau
Journal:  Int J Biochem Cell Biol       Date:  2008-08-15       Impact factor: 5.085

9.  Identification of glycosylated 38-kDa connective tissue growth factor (IGFBP-related protein 2) and proteolytic fragments in human biological fluids, and up-regulation of IGFBP-rP2 expression by TGF-beta in Hs578T human breast cancer cells.

Authors:  D H Yang; H S Kim; E M Wilson; R G Rosenfeld; Y Oh
Journal:  J Clin Endocrinol Metab       Date:  1998-07       Impact factor: 5.958

10.  Normal growth and development in mice over-expressing the CCN family member WISP3.

Authors:  Yukio Nakamura; Yajun Cui; Carol Fernando; Wendy E Kutz; Matthew L Warman
Journal:  J Cell Commun Signal       Date:  2009-04-29       Impact factor: 5.782

View more
  22 in total

Review 1.  Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets.

Authors:  Joon-Il Jun; Lester F Lau
Journal:  Nat Rev Drug Discov       Date:  2011-12-01       Impact factor: 84.694

Review 2.  Kallikreins - The melting pot of activity and function.

Authors:  Magdalena Kalinska; Ulf Meyer-Hoffert; Tomasz Kantyka; Jan Potempa
Journal:  Biochimie       Date:  2015-09-25       Impact factor: 4.079

3.  The matricellular protein CCN1 controls retinal angiogenesis by targeting VEGF, Src homology 2 domain phosphatase-1 and Notch signaling.

Authors:  Hemabindu Chintala; Izabela Krupska; Lulu Yan; Lester Lau; Maria Grant; Brahim Chaqour
Journal:  Development       Date:  2015-05-22       Impact factor: 6.868

4.  Novel Biological Substrates of Human Kallikrein 7 Identified through Degradomics.

Authors:  Yijing Yu; Ioannis Prassas; Apostolos Dimitromanolakis; Eleftherios P Diamandis
Journal:  J Biol Chem       Date:  2015-06-01       Impact factor: 5.157

5.  Connective tissue growth factor (CCN2) is a matricellular preproprotein controlled by proteolytic activation.

Authors:  Ole Jørgen Kaasbøll; Ashish K Gadicherla; Jian-Hua Wang; Vivi Talstad Monsen; Else Marie Valbjørn Hagelin; Meng-Qiu Dong; Håvard Attramadal
Journal:  J Biol Chem       Date:  2018-09-27       Impact factor: 5.157

6.  Regulating the regulators of angiogenesis by CCN1 and taking it up a Notch.

Authors:  Brahim Chaqour
Journal:  J Cell Commun Signal       Date:  2016-05-04       Impact factor: 5.782

7.  Degradome products of the matricellular protein CCN1 as modulators of pathological angiogenesis in the retina.

Authors:  Jinok Choi; Ann Lin; Eric Shrier; Lester F Lau; Maria B Grant; Brahim Chaqour
Journal:  J Biol Chem       Date:  2013-06-24       Impact factor: 5.157

Review 8.  Caught between a "Rho" and a hard place: are CCN1/CYR61 and CCN2/CTGF the arbiters of microvascular stiffness?

Authors:  Brahim Chaqour
Journal:  J Cell Commun Signal       Date:  2019-08-02       Impact factor: 5.782

9.  CCN1 secretion and cleavage regulate the lung epithelial cell functions after cigarette smoke.

Authors:  Hyung-Geun Moon; Sang-Heon Kim; Jinming Gao; Taihao Quan; Zhaoping Qin; Juan C Osorio; Ivan O Rosas; Min Wu; Yohannes Tesfaigzi; Yang Jin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-06-27       Impact factor: 5.464

10.  Proteolytic processing of connective tissue growth factor in normal ocular tissues and during corneal wound healing.

Authors:  Paulette M Robinson; Tyler S Smith; Dilan Patel; Meera Dave; Alfred S Lewin; Liya Pi; Edward W Scott; Sonal S Tuli; Gregory S Schultz
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-12-13       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.